Deals

After launching at the end of 2022, IBSA’s dedicated US authorized generics and complex generics unit, Yaral Pharma, has brought on board another of its parent company’s products.

Boehringer Ingelheim is partnering with GoodRx in the US to offer a version of its Humira biosimilar at a 92% discount to the brand’s list price. Generics Bulletin spoke with Chris Marsh, Boehringer’s senior vice president of value and access, about the initiative.

ANI has acquired Alimera Sciences in a move to expand its rare disease business, highlighting its increasing drift from generics.

After announcing a pivot to innovative oncology treatments from biosimilars, Coherus has granted an exclusive license for its novel biologic cancer therapy Loqtorzi to Apotex in Canada.

UK liquids specialist Rosemont Pharmaceuticals has delivered on promises to expand into the US market by striking a deal to acquire Georgia-based distributor Sabal Therapeutics.

Just-Evotec Biologics has announced an expansion of its partnership with Sandoz to develop and manufacture biosimilars.

Amneal has revealed the latest addition to its biosimilars pipeline, in the form of an omalizumab rival to Xolair developed by Kashiv Biosciences.

Teva enjoyed a favorable tax status for years in its domestic Israel. However, after the firm battled in court against challenges to its historic tax payments, Teva has now agreed a three-quarters-of-a-billion dollar settlement agreement with the Israel Tax Authority.

Italy’s Olon Group has acquired French biotech contract development and manufacturing organization GTP Bioways, in a move that Olon says will allow it to “expand and diversify its technological offerings.”

Two major Indian players have formed an alliance to bring a biosimilar to Genentech’s Perjeta to their local market, having already debuted several treatments in the HER2-positive breast cancer space.

Following on from the recently announced closing of a Saudi Arabia-focused fund, TVM Capital has doubled down on its local efforts with a further $35m investment into Boston Oncology Arabia’s efforts.

The Indian player made another high-level deal that grants it rights to nicotine replacement therapies in over 30 countries, following on from its recent announcements with Nestlé.

In long-running litigation over perindopril ‘pay for delay’ settlements, appeals have been refused and certain earlier findings by Europe’s general court have been set aside in a fresh ruling by the Court of Justice of the EU.

Meitheal Pharmaceuticals can begin preparations for a seminal moment, the firm’s first marketed US biosimilar, as it snapped up rights to Humira rival Yusimry from Coherus BioSciences.

In an effort to set themselves apart from other Japanese companies, Kidswell and Chiome have signed a deal focused on the co-development of new biosimilars and profit sharing.

Having earlier this year outlined plans for international expansion, liquids specialist Rosemont has made its first venture outside the UK by acquiring Greek R&D organization Pharma-Data.